GlassScriptPhysician profile
Oleg Dulkin
NPI 1942299292
$2,676.81
in general payments reported to CMS, 2019-2025
29 companies · $41.61 in 2025
The $41.61 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $254 · 2021: $545 · 2022: $276 · 2023: $344 · 2024: $282 · 2025: $41.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $530.11 | 2019-2024 | |
| Glaxosmithkline, LLC. | $287.10 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $234.38 | 2019-2024 | Xarelto |
| Csl Behring | $169.02 | 2019-2023 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $162.33 | 2019-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.50 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $139.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $133.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $116.83 | 2019-2024 | Airsupra |
| Merck Sharp & Dohme LLC | $95.73 | 2019-2023 | Verquvo, Belsomra |
| Lilly USA, LLC | $78.32 | 2020-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $70.65 | 2020-2023 | Ozempic, Rybelsus |
| Baxter Healthcare | $56.80 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Otsuka America Pharmaceutical, INC. | $52.78 | 2019-2025 | Rexulti |
| Gilead Sciences, INC. | $52.38 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.68 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.82 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.89 | 2019 | |
| Ucb, INC. | $29.40 | 2024 | Nayzilam |
| Abbott Laboratories | $28.35 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $24.94 | 2019 | |
| Amgen INC. | $24.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.74 | 2024 | |
| Ibsa Pharma INC. | $19.14 | 2021 | |
| Abbvie INC. | $18.18 | 2024 | |
| Vapotherm INC | $18.01 | 2021 | |
| Smith+Nephew, INC. | $13.80 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.67 | 2023 | Gvoke Hypopen |
| Genentech USA, INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleg Dulkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.